Downtrend on the daily chart: below its 200-day average, above its 50-day · 50-day below the 200-day · SuperTrend down since Mar 3 · inside the Ichimoku cloud · RSI 24 (oversold) · MACD above its signal · at its 52-week low
None of the 29 investors followed here reported a position in EMGE in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a EMGE trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
No insider transactions reported for EMGE.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 0.0 | 200.0 | -66.7 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0% | ||
| 2025 | -11.1 | 0.0 | -12.5 | 28.6 | -77.8 | 0.0 | 0.0 | -50.0 | 0.0 | 0.0 | 100.0 | -50.0 | −88.9% |
| 2024 | 385.7 | -50.0 | -5.9 | 12.5 | -22.2 | 50.0 | -21.4 | -6.1 | -12.9 | -18.5 | -9.1 | -10.0 | +28.6% |
| 2023 | 17.5 | -29.8 | -27.3 | 25.0 | 6.7 | -12.5 | 0.0 | -71.4 | 6.3 | 5.9 | 0.0 | -22.2 | −82.5% |
| 2022 | -42.9 | -68.8 | -10.0 | -11.1 | -41.3 | 102.1 | 275.8 | -68.6 | -18.7 | -29.1 | -27.1 | -14.9 | −92.9% |
| 2021 | 26.6 | -20.7 | 7.8 | -26.0 | 108.4 | -48.7 | -47.0 | 54.8 | 16.0 | -11.9 | 2.2 | 7.3 | −21.2% |
| 2020 | 0.0 | -11.1 | -46.2 | 1.2 | 49.4 | 38.5 | 0.0 | -37.8 | 147.7 | 6.7 | -5.4 | -49.2 | −21.0% |
| 2019 | 14.5 | -17.9 | 105.1 | 37.5 | -36.4 | 42.9 | 19.9 | -17.9 | 17.6 | 3.6 | 0.0 | -25.0 | +116.9% |
| 2018 | -17.4 | -9.2 | 1.3 | 360.5 | 111.4 | 100.0 | -27.0 | 0.0 | -62.0 | 24.4 | -17.6 | -1.2 | +315.0% |
| 2017 | 0.0 | -76.5 | 0.0 | 184.5 | -61.2 | 50.5 | -36.2 | 0.0 | -26.4 | -35.9 | 0.0 | 0.0 | −88.2% |
| 2016 | -18.0 | 0.0 | -20.0 | 37.4 | -38.1 | 47.1 | -32.0 | -11.8 | 8.5 | 22.9 | 100.0 | 6.3 | +39.3% |
| 2015 | -21.6 | -17.2 | -47.9 | 23.9 | -3.3 | -30.0 | 4.8 | -31.8 | -46.7 | 0.0 | 0.0 | -23.7 | −91.8% |
| 2014 | 0.0 | 0.0 | 185.7 | -29.8 | 21.0 | 5.9 | 5.6 | 47.4 | -7.1 | -15.4 | 159.1 | 29.8 | +957.1% |
| 2013 | 66.7 | 2.0 | -2.0 | -40.0 | -16.7 | 20.0 | 100.0 | 0.0 | -58.3 | 100.0 | -48.3 | 35.4 | +16.7% |
| 2012 | 2.9 | 94.4 | 19.3 | 49.7 | -55.5 | 34.9 | 0.0 | 0.0 | 33.3 | -20.0 | -87.5 | 200.0 | −14.3% |
| 2011 | 0.0 | 2200.0 | -65.2 | 50.0 | 0.0 | -33.3 | 50.0 | 0.0 | 50.0 | -44.4 | -20.0 | -12.5 | +600.0% |
| 2010 | 50.0 | -55.6 | 0.0 | -5.0 | -42.1 | 36.4 | -33.3 | 0.0 | 0.0 | 0.0 | 0.0 | -90.0 | −96.7% |
| 2009 | -57.3 | -49.4 | -25.0 | −83.8% |
No analyst coverage for this instrument.
Emergent Health Corp. develops and sells regenerative medicine, neutraceuticals, and phytonutritionals. Its products comprise Vita-Stim, a nutrient that enhances the immune system, nourishes stem cells, and maintains health; Neuvitale, which nourishes stem cells and acts as a methyl donor to protect DNA; Hungarest, a diet aid that controls appetite in the brain and stomach; EmergentO2, water oxygenator, which increases oxygen in the blood stream; and products for reducing facial wrinkles. The company distributes its products through health food stores, pharmacies, and various other retail outlets throughout the United States and internationally. Emergent Health Corp. was incorporated in 2006 and is based in King of Prussia, Pennsylvania. As of August 26, 2014, Emergent Health Corp was taken private.
No recent headlines.